File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: HPV vaccination in women over 25 years of age: Asian cervical cancer prevention advisory board recommendations

TitleHPV vaccination in women over 25 years of age: Asian cervical cancer prevention advisory board recommendations
Authors
Issue Date2009
Citation
Journal Of Obstetrics And Gynaecology Research, 2009, v. 35 n. 4, p. 712-716 How to Cite?
AbstractCervical cancer is the second most common cancer among women worldwide and is responsible for more than 270 000 deaths every year, the majority of which occur in Asia. The Asian Cervical Cancer Prevention Advisory Board (ACCPAB) was established in 2005 with a mission to raise awareness of the significant disease burden of cervical cancer in Asia and the strategies for its prevention. Persistent infection with oncogenic subtypes of human papillomavirus (HPV) is the necessary cause of cervical cancer. Vaccines against the two most carcinogenic subtypes of HPV (HPV 16 and 18) are available and have the potential to prevent cervical cancer in 70-80% of HPV- naïve women. HPV vaccines have been first licensed for use in girls and women aged 9-26 years. However, women over 25 years of age are also vulnerable to HPV infection and are likely to benefit from vaccination. Current evidence shows that even women previously infected with HPV who have subsequently cleared the infection can obtain complete protection against the HPV types contained in the vaccines. Therefore, vaccinating sexually active women aged over 25 years offers significant benefits and may be expected to decrease the incidence of cervical cancer. The ACCPAB advocates the adoption of preventive measures against HPV infection, including vaccination, with a view to protecting women of all ages from developing cervical cancer. © 2009 Japan Society of Obstetrics and Gynecology.
Persistent Identifierhttp://hdl.handle.net/10722/173351
ISSN
2015 Impact Factor: 1.091
2015 SCImago Journal Rankings: 0.521
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorBasu, Pen_US
dc.contributor.authorNgan, HYSen_US
dc.contributor.authorHseon, TEen_US
dc.date.accessioned2012-10-30T06:29:32Z-
dc.date.available2012-10-30T06:29:32Z-
dc.date.issued2009en_US
dc.identifier.citationJournal Of Obstetrics And Gynaecology Research, 2009, v. 35 n. 4, p. 712-716en_US
dc.identifier.issn1341-8076en_US
dc.identifier.urihttp://hdl.handle.net/10722/173351-
dc.description.abstractCervical cancer is the second most common cancer among women worldwide and is responsible for more than 270 000 deaths every year, the majority of which occur in Asia. The Asian Cervical Cancer Prevention Advisory Board (ACCPAB) was established in 2005 with a mission to raise awareness of the significant disease burden of cervical cancer in Asia and the strategies for its prevention. Persistent infection with oncogenic subtypes of human papillomavirus (HPV) is the necessary cause of cervical cancer. Vaccines against the two most carcinogenic subtypes of HPV (HPV 16 and 18) are available and have the potential to prevent cervical cancer in 70-80% of HPV- naïve women. HPV vaccines have been first licensed for use in girls and women aged 9-26 years. However, women over 25 years of age are also vulnerable to HPV infection and are likely to benefit from vaccination. Current evidence shows that even women previously infected with HPV who have subsequently cleared the infection can obtain complete protection against the HPV types contained in the vaccines. Therefore, vaccinating sexually active women aged over 25 years offers significant benefits and may be expected to decrease the incidence of cervical cancer. The ACCPAB advocates the adoption of preventive measures against HPV infection, including vaccination, with a view to protecting women of all ages from developing cervical cancer. © 2009 Japan Society of Obstetrics and Gynecology.en_US
dc.languageengen_US
dc.relation.ispartofJournal of Obstetrics and Gynaecology Researchen_US
dc.subject.meshAdulten_US
dc.subject.meshAge Factorsen_US
dc.subject.meshAsiaen_US
dc.subject.meshCervical Intraepithelial Neoplasia - Prevention & Controlen_US
dc.subject.meshFemaleen_US
dc.subject.meshHuman Papillomavirus 16en_US
dc.subject.meshHuman Papillomavirus 18en_US
dc.subject.meshHumansen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshPapillomavirus Vaccines - Immunologyen_US
dc.subject.meshUterine Cervical Neoplasms - Prevention & Controlen_US
dc.subject.meshVaccinationen_US
dc.subject.meshVaginal Smearsen_US
dc.titleHPV vaccination in women over 25 years of age: Asian cervical cancer prevention advisory board recommendationsen_US
dc.typeArticleen_US
dc.identifier.emailNgan, HYS:hysngan@hkucc.hku.hken_US
dc.identifier.authorityNgan, HYS=rp00346en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1111/j.1447-0756.2009.01022.xen_US
dc.identifier.pmid19751332-
dc.identifier.scopuseid_2-s2.0-70049097927en_US
dc.identifier.hkuros170614-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-70049097927&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume35en_US
dc.identifier.issue4en_US
dc.identifier.spage712en_US
dc.identifier.epage716en_US
dc.identifier.isiWOS:000270030700015-
dc.publisher.placeAustraliaen_US
dc.identifier.scopusauthoridBasu, P=35499083600en_US
dc.identifier.scopusauthoridNgan, HYS=34571944100en_US
dc.identifier.scopusauthoridHseon, TE=26422061100en_US
dc.identifier.citeulike5785831-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats